

ASX ANNOUNCEMENT

NOTICE UNDER SECTION 708A OF THE CORPORATIONS ACT 2001

28th April 2016: Analytica Ltd (**Company**), manufacturer of the PeriCoach® system, advises that the Company has successfully completed the following share placements:

- a. on 26th April 2016, subsequent to shareholder approval at the Company's Extraordinary General Meeting, the Company issued 333,333,333 fully paid ordinary shares in the Company at 0.3 cents per share to an entity associated with Non-executive Chairman, Dr Michael Monsour (**Monsour Shares**); and
- b. on 28th April 2016, the Company issued 202,324,638 fully paid ordinary shares in the Company at 0.255 cents per share to a new cornerstone investor (**Cornerstone Investor Shares**). This issue was conditional on shareholders approving the placement of the Monsour Shares.

As required under section 708A(6) of the Corporations Act 2001 (Act), the Company gives notice that:

1. The Monsour Shares and Cornerstone Investor Shares were issued without disclosure under Part 6D.2 of the Act.
2. This notice is being given under section 708A(5)(e) of the Act.
3. As at the date of this notice, the Company has complied with:
 - a. the provisions of Chapter 2M of the Act as they apply to the Company; and
 - b. section 674 of the Act.
4. As at the date of this notice, there is no excluded information as defined in section 708A(7) and section 708A(8) of the Act which is required to be disclosed by the Company.

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

Follow us on:



About Analytica Limited



Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to PeriCloud where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition.

PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The product is available for sale in Australia and New Zealand, UK and Ireland, and in the USA by prescription.